Literature DB >> 17336323

A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.

Maurizio Chiriva-Internati1, Fabio Grizzi, Jon A Weidanz, Raffaele Ferrari, Yu Yuefei, Beatriz Velez, Michael H Shearer, Devin B Lowe, Eldo E Frezza, Everardo Cobos, W Martin Kast, Ronald C Kennedy.   

Abstract

No experimental animal model employing a primary human ovarian carcinoma (OC) cell line is presently available that tracks the progression of this cell line with an identifiable marker. This hinders investigations related to developing new approaches for treating OC. Here, we describe the development of a tumor model in NOD/SCID mice for human OC that makes use of the endogenously expressed tumor specific sperm protein 17 (Sp17) cancer testis antigen. In this model, human SKOV-3 OC cell lines were intra-peritoneally seeded. Subsequently viable SKOV-3 cells were recovered from primary organ cell cultures from the liver ovaries, abdomen, and ascitic fluid, and their presence was confirmed by the detection of Sp17 mRNA by RT-PCR and Sp17 protein by immunocytochemistry and FACS analysis. When SKOV-3 tumor cells were administered intravenously the mice developed primarily lung tumor foci. This model makes it possible to evaluate new immunotherapeutic strategies for the treatment of human OC based on the biomarker Sp17.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336323     DOI: 10.1016/j.jim.2007.01.010

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  The effect of down regulation of calcineurin Aα by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis.

Authors:  Ning-Qiang Ma; Li-Li Liu; Jie Min; Jun-Wei Wang; Wei-Feng Jiang; Yan Liu; Yan-Guo Feng; Hai-Chuan Su; Ying-Ming Feng; He-Long Zhang
Journal:  Clin Exp Metastasis       Date:  2011-07-23       Impact factor: 5.150

2.  Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.

Authors:  Zewei Tu; Jie Peng; Xiaoyan Long; Jingying Li; Lei Wu; Kai Huang; Xingen Zhu
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

3.  Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Authors:  Maurizio Chiriva-Internati; Yuefei Yu; Leonardo Mirandola; Marjorie R Jenkins; Caroline Chapman; Martin Cannon; Everardo Cobos; W Martin Kast
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

4.  Potential target antigens for a universal vaccine in epithelial ovarian cancer.

Authors:  Renee Vermeij; Toos Daemen; Geertruida H de Bock; Pauline de Graeff; Ninke Leffers; Annechien Lambeck; Klaske A ten Hoor; Harry Hollema; Ate G J van der Zee; Hans W Nijman
Journal:  Clin Dev Immunol       Date:  2010-09-15

5.  Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.

Authors:  Leonardo Mirandola; Elisa Pedretti; Jose A Figueroa; Raffaella Chiaramonte; Michela Colombo; Caroline Chapman; Fabio Grizzi; Federica Patrinicola; W Martin Kast; Diane D Nguyen; Rakhshanda Layeequr Rahman; Naval Daver; Peter Ruvolo; Sean M Post; Robert S Bresalier; Maurizio Chiriva-Internati
Journal:  Oncotarget       Date:  2017-08-10

6.  A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade.

Authors:  Leonardo Mirandola; Maurizio Chiriva-Internati; Robert Bresalier; Lucia Piccotti; Fabio Grizzi; Francesco M Marincola
Journal:  J Transl Med       Date:  2019-12-19       Impact factor: 5.531

7.  The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.

Authors:  Christopher A Schutt; Leonardo Mirandola; Jose A Figueroa; Diane D Nguyen; Joehassin Cordero; Klauss Bumm; Benjamin L Judson; Maurizio Chiriva-Internati
Journal:  Oncotarget       Date:  2017-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.